ビリジアン・セラピューティクス
Viridian Therapeutics, Inc.
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q2 | -1.05 | $284,000 | -$107M |
| 2026 Q1 | -1.03 | $141,000 | -$120M |
| 2025 Q4 | -1.11 | $132,000 | -$24M |
| 2025 Q3 | -0.34 | $71M | -$85M |
| 2025 Q2 | -1.23 | $75,000 | -$75M |
| 2025 Q1 | -0.87 | $72,000 | -$93M |
| 2024 Q4 |
| -0.81 |
| $72,000 |
| -$73M |
| 2024 Q3 | -1.15 | $86,000 | -$68M |